Retrospective Cohort Study | Nirmatrelvir use and severe Covid-19 outcomes during the Omicron surge.
25 Aug, 2022 | 12:08h | UTC
Commentary on Twitter
During the clinical rollout of nirmatrelvir in Israel in early 2022, most patients (78%) had previous SARS-CoV-2 immunity. Benefit was seen among patients at highest risk for Covid-19 progression, such as those 65+. https://t.co/O6CxzDdIfH pic.twitter.com/ccCaCCh15i
— NEJM (@NEJM) August 24, 2022